My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 9 521 / DOI: 10.3332/ecancer.2015.521

Clinical Study

Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent

Itraconazole, a common triazole anti-fungal drug in widespread clinical use, has evidence of clinical activity that is of interest in oncology. There is evidence that at the clinically relevant doses, itraconazole has potent anti-angiogenic activity, and that it can inhibit the Hedgehog signalling pathway and may also induce autophagic growth arrest. The evidence for these anticancer effects, in vitro, in vivo, and clinical are summarised, and the putative mechanisms of their action outlined. Clinical trials have shown that patients with prostate, lung, and basal cell carcinoma have benefited from treatment with itraconazole, and there are additional reports of activity in leukaemia, ovarian, breast, and pancreatic cancers. Given the evidence presented, a case is made that itraconazole warrants further clinical investigation as an anti-cancer agent. Additionally, based on the properties summarised previously, it is proposed that itraconazole may synergise with a range of other drugs to enhance the anti-cancer effect, and some of these possible combinations are presented in the supplementary materials accompanying this paper.

Keywords: Drug repurposing, itraconazole, Hedgehog pathway inhibition, ReDO project

Loading Article Metrics ... Please wait

Related articles

Case Report: Use of PEG-asparaginase in monomorphic epitheliotropic intestinal T-cell lymphoma, a disease with diagnostic and therapeutic challenges

Abstract | Full Article | PDF Published: 27 Sep 2017 / DOI: 10.3332/ecancer.2017.771

Conference Report: Highlights from the WIN 2017 Symposium, 26–27 June 2017, Paris, France: ‘Expediting Global Innovation in Precision Cancer Medicine’

Abstract | Full Article | PDF Published: 27 Sep 2017 / DOI: 10.3332/ecancer.2017.770

Clinical Study: Expression of ERCC1, Bcl-2, Lin28a, and Ki-67 as biomarkers of response to first-line platinum-based chemotherapy in patients with high-grade extrapulmonary neuroendocrine carcinomas or small cell lung cancer

Abstract | Full Article | PDF Published: 11 Sep 2017 / DOI: 10.3332/ecancer.2017.767

Short Communication: The cost of cancer treatment in Portugal

Abstract | Full Article | PDF | Portuguese Published: 06 Sep 2017 / DOI: 10.3332/ecancer.2017.765

Short Communication: Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines

Abstract | Full Article | PDF Published: 04 Sep 2017 / DOI: 10.3332/ecancer.2017.764



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence